🔗 Share this article

A shadow economy for unapproved slimming drugs is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.

Investigational Treatment Gaining Popularity Via Social Media

The experimental drug, which remains in clinical trials, is being promoted by online personalities for its alleged weight-reducing effects. Viewers are urged to contact these profiles privately for source information, while also obtaining discount codes.

Active Commerce on Social Networks

Separately, a flourishing trade exists on messaging services, where communities with thousands of participants share “before and after” photos, administration instructions and claims of next-day UK delivery. Vendors market the substance there before redirecting buyers to other platforms for transactions.

Learning About Retatrutide

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could help patients lose up to 25% of their body weight. Nicknamed the “triple G”, the drug is being hailed online as the next Ozempic.

Medical Professionals Voice Concerns

However, physicians and chemists have warned that the distribution of what is still an unapproved drug in the UK is a cause for concern and could result in individuals administering products of uncertain source.

Several experts said the demand for the experimental drug could be connected to the increasing price of licensed slimming treatments such as Mounjaro.

Regulatory Position and Implementation

Selling retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that must not be promoted or distributed for human use under the British medical regulations.

Some content creators try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but promotion and distribution can still violate pharmaceutical, advertising, and customer regulations, risking penalties, legal action or prison.

Platform Response and Material Elimination

According to TikTok, the platform has removed violative material and banned associated hashtags and search suggestions. The company stated it was committed to keeping the service safe and allocating resources in enhancing compliance measures.

Digital Trading Operations

Research also discovered communities with up to nine thousand participants marketing retatrutide using Telegram's built-in discovery tool, which functions like a online catalog. Entering “retatrutide” instantly displays groups with thousands of members, filled with images of slimming results, glowing testimonials and step-by-step instructions for preparing or injecting at residence.

Within moments of entering one group, a seller shared WhatsApp details, where the majority of transactions take place. The seller provided an guidebook and promised shipping within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a image of a alleged testing documentation. None asked about weight, medical conditions or past usage.

Product Information and Costs

Within these groups, messages display black plastic packages with Royal Mail labels, claiming to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with sterile water, or ready-to-use injectors usually sold at 160 pounds for 20mg. When questioned how long a injector should be used, sellers give contradictory responses varying between a several days to “depends on your body”.

Service Oversight and Security Actions

A representative for Telegram stated it actively monitored harmful material on its platform including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are injecting materials they cannot confirm. Even if the science behind retatrutide is sound, these digital versions may not contain what they advertise,” stated Jason Murphy, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With costs increasing, patients are using online platforms. But counterfeit injections are highly risky. You cannot know what’s contained or whether the conditions they were produced in was sterile,” she said.

Her staff has previously seen individuals harmed by self-injection from unconfirmed sources. “We recognize the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” said Wyllie. “These substances could be impure or improperly measured.”

Manufacturer Statement

A spokesperson from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for human use,” they said, noting that any item “falsely representing itself as a Lilly experimental substance not yet authorized … may subject users to possibly significant medical dangers”.